Wealthfront Advisers LLC bought a new stake in HealthEquity, Inc. (NASDAQ:HQY – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 107,390,188 shares of the company’s stock, valued at approximately $10,304,089,000. HealthEquity accounts for 8.5% of Wealthfront Advisers LLC’s investment portfolio, making the stock its 3rd biggest holding. Wealthfront Advisers LLC owned approximately 123.92% of HealthEquity as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC boosted its position in HealthEquity by 34.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 384 shares of the company’s stock worth $37,000 after acquiring an additional 98 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in HealthEquity by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 24,200 shares of the company’s stock worth $2,322,000 after acquiring an additional 100 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in HealthEquity by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 17,776 shares of the company’s stock worth $1,706,000 after acquiring an additional 100 shares during the last quarter. State of Michigan Retirement System boosted its position in HealthEquity by 0.5% during the fourth quarter. State of Michigan Retirement System now owns 20,722 shares of the company’s stock worth $1,988,000 after acquiring an additional 100 shares during the last quarter. Finally, Raymond James Trust N.A. boosted its position in HealthEquity by 4.8% during the third quarter. Raymond James Trust N.A. now owns 2,905 shares of the company’s stock worth $238,000 after acquiring an additional 132 shares during the last quarter. Institutional investors and hedge funds own 99.55% of the company’s stock.
HealthEquity Price Performance
HealthEquity stock opened at $94.48 on Tuesday. The company’s 50 day simple moving average is $105.80 and its 200-day simple moving average is $94.66. The company has a market capitalization of $8.19 billion, a price-to-earnings ratio of 86.68, a price-to-earnings-growth ratio of 1.60 and a beta of 0.62. HealthEquity, Inc. has a 1 year low of $65.01 and a 1 year high of $115.59. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20.
Insider Buying and Selling
In other HealthEquity news, Director Stuart B. Parker sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $96.72, for a total transaction of $2,418,000.00. Following the completion of the transaction, the director now owns 19,061 shares in the company, valued at $1,843,579.92. The trade was a 56.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert W. Selander sold 5,750 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the transaction, the director now owns 78,219 shares of the company’s stock, valued at $8,704,992.51. This trade represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. 2.20% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on HQY. The Goldman Sachs Group began coverage on shares of HealthEquity in a research report on Friday, November 15th. They set a “neutral” rating and a $108.00 price target on the stock. Wells Fargo & Company boosted their price target on shares of HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. JMP Securities lifted their target price on shares of HealthEquity from $105.00 to $107.00 and gave the stock a “market outperform” rating in a research note on Tuesday, December 10th. Raymond James lifted their target price on shares of HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 25th. Finally, Bank of America lifted their target price on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, HealthEquity has a consensus rating of “Moderate Buy” and a consensus price target of $113.54.
HealthEquity Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories
- Five stocks we like better than HealthEquity
- Should You Invest in Penny Stocks?
- How to Protect Your Portfolio When Inflation Is Rising
- What is a penny stock? A comprehensive guide
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- 3 Fintech Stocks With Good 2021 Prospects
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.